Document is current
Any future updates will be listed below
-
Authors
Tabuchi, Isao
Ogawa, Aiko
Shigetoshi, Masataka
Shimokawahara, Hiroto
Ito, Hiroshi
Matsubara, Hiromi https://orcid.org/0000-0002-3417-7651
- License Information
-
More Information
Article History
Received: 7 November 2021
Accepted: 30 May 2022
First Online: 22 June 2022
Declarations
:
: Dr. Ogawa received lecture fees from Nippon Shinyaku, Co., Ltd.; Pfizer Japan, Inc.; and Actelion Japan, Ltd. Dr. Shimokawahara received lecture fees from Daiichi Sankyo Co., Ltd.; Bayer Yakuhin, Ltd.; Nippon Shinyaku, Co., Ltd.; Actelion Pharmaceuticals Japan, Ltd.; and received research funding from Bayer Yakuhin, Ltd. Dr. Matsubara received lecture fees from Nippon Shinyaku, Co., Ltd.; Bayer AG; Pfizer Japan, Inc.; Actelion Pharmaceuticals Ltd.; GlaxoSmithKline plc.; United Therapeutics Corp.; AOP Orphan Pharmaceuticals AG.; Grupo Ferrer Internacional SA.; and Kaneka Medix Co. Dr. Ogawa and Dr. Matsubara are involved in collaborative research with Nippon Shinyaku, Co., Ltd. Other authors report no conflicts.
